Medulloepithelioma of the central nervous system

Medulloepithelioma of the central nervous system is an extremely rare and highly malignant embryonal tumor that arises from the primitive neuroepithelial cells of the brain or spinal cord. It is classified among the embryonal tumors of the central nervous system by the World Health Organization (WHO) and is considered a grade IV neoplasm. This tumor most commonly occurs in young children, typically presenting in the first few years of life. Medulloepitheliomas are characterized by the formation of tubular or papillary structures that resemble the embryonic neural tube, distinguishing them histologically from other primitive neuroectodermal tumors. The tumor primarily affects the brain, with a predilection for the cerebral hemispheres, though it can also arise in the posterior fossa, brainstem, or spinal cord. Key symptoms depend on the tumor's location and may include increased intracranial pressure (presenting as headaches, vomiting, and lethargy), seizures, focal neurological deficits, hydrocephalus, and failure to thrive. Rapid tumor growth can lead to a swift clinical deterioration. Some medulloepitheliomas may contain divergent differentiation with mesenchymal elements such as cartilage, bone, or muscle, and these are classified as medulloepithelioma with teratoid features. The prognosis for central nervous system medulloepithelioma is generally poor, though outcomes vary depending on the extent of surgical resection and the child's age at diagnosis. Treatment typically involves maximal safe surgical resection followed by adjuvant chemotherapy and, in older children, radiation therapy. Due to the rarity of this tumor, there are no standardized treatment protocols, and management is often guided by experience with other high-grade embryonal tumors such as medulloblastoma and atypical teratoid/rhabdoid tumor. Enrollment in clinical trials is encouraged when available.

Common questions about Medulloepithelioma of the central nervous system